The Phase-2 Flex, The Diet King’s Crown, and The CEO Sell-Signal

A small biotech just flashed encouraging data, the weight-loss winner got a free boost, and a packaging name got spooked by a top-boss sale. We’ll lay out the clean entries, the one level to respect, and where to stay patient.

Something big is happening in energy — right now.

An MIT genius has cracked a way to tap an energy source that never runs out.

The U.S. Department of Energy says it’s enough to power the planet for billions of years.

Big Tech isn’t waiting — they’re already racing to position themselves.

Here’s what’s driving the rush.

Futures are sliding after Trump said he is raising the global tariff rate to 15%, keeping markets stuck in trade-policy limbo. Oil and bitcoin are both weaker, and traders are bracing for a headline-heavy week with Nvidia earnings in focus.

Elite Trade Club now offers text alerts — so you get trending stocks and market-moving news sent straight to your phone before the bell.

Email’s great. Texts are faster.

👉 Click here to get our pre-market report to your cell for free!

You’ll be first in line when the market starts moving.

Earnings (Premarket):
• Dominion Energy, Inc. [D]
• Domino's Pizza Inc [DPZ]
• Emera Incorporated [EMA]

Earnings (Aftermarket):
• ONEOK, Inc. [OKE]
• Diamondback Energy, Inc. [FANG]
• Keysight Technologies Inc. [KEYS]
• BWX Technologies, Inc. [BWXT]
• Viper Energy, Inc. [VNOM]

Economic Reports:
• Fed governor Christopher Waller speaks: 8:00 am
• Factory orders (Dec): 10:00 am

MoonLake Immunotherapeutics (NASDAQ: MLTX) posted upbeat Phase 2 results in axial spondyloarthritis, and the market reacted as if it just found an extra fry at the bottom of the bag. Big response rates, clear improvement signals, and no surprise safety drama are basically the trifecta for a mid-cap biotech trying to earn trust.

The catch is always the same: good Phase 2 news is the movie trailer, not the full film. It can be awesome, but the market will quickly ask what the Phase 3 plan looks like, how long it takes, and how much cash it burns to get there. The good news is MoonLake says it has a runway, which matters when the next chapters are expensive.

This is also the kind of stock that can pop on Monday and give some of it back by Wednesday, because biotech traders treat volatility like a hobby. The smarter play is to let the initial excitement cool, then decide if you want to own the story for the next data checkpoint.

My Take For You: If you are new, wait for a pullback and start small. If you own it, consider trimming into strength and keeping a starter position for the next update.

My Verdict: High-upside biotech, but trade it with a leash until the next trial steps are crystal clear.

Eli Lilly and Company (NYSE: LLY) caught a tailwind after a competitor’s next-gen weight loss drug stumbled in a head-to-head style test. That is the biotech version of your fastest rival tripping in gym class while you keep jogging. The market heard one thing: the leader stays the leader, at least for now.

This matters because weight loss is not just a hot product cycle; it is a whole profit ecosystem: demand, pricing, doctors’ habits, and a pipeline of follow-on drugs. When a challenger underwhelms, it can reinforce the idea that the current winner has more time to scale, defend, and expand.

But do not treat this like a guaranteed straight line up. This stock is already a heavyweight, and heavyweights do not sprint forever without water breaks. If you chase a big green day, you are basically paying extra for the same sandwich. The better approach is patience: wait for a calmer entry or buy in small bites.

My Take For You: Starter buy only on a dip, add if the story stays clean, and do not over-size a name this big.

My Verdict: High-quality leader, but your edge comes from timing, not hype.

For decades, one type of investment was reserved for the ultra-wealthy.

Then Trump signed Executive Order 14330 - and opened it to everyone.

Now you can get into this boom for less than $20.

See what changed

Smurfit WestRock plc (NYSE: SW) is sliding after news that the CEO sold shares, and the market took it personally. Fair or not, insider selling headlines spook people because they read like a tiny vote of no confidence, even when the business story has not changed overnight.

Here is the more boring truth: insiders sell for lots of reasons. Taxes, planning, diversification, life stuff. But markets do not trade on nuance at 7 a.m. They trade on vibes, and this one is a classic short-term confidence hit for a stock that was already dealing with merger integration and a watchful crowd.

So the play is not to panic-sell just because a headline yelled at you. It is to watch how the stock behaves after the first wave of selling. If it stabilizes and starts acting normal again, that is your signal that the market has digested it. If it keeps leaking, let it fall into a better spot before you even think about stepping in.

My Take For You: If you want in, wait for it to settle and start small. If you own it, avoid emotional selling and set a clear line where you would cut risk.

My Verdict: Solid business, noisy headline. Worth watching, but let price action prove it is done sulking.

JPMorgan downgraded VFC and cut profit forecasts, which is basically Wall Street saying the turnaround is still on training wheels.

Retail names can stay in the penalty box after a call like that, even if the brands are iconic.

Novo’s experimental obesity drug CagriSema missed a key endpoint against Eli Lilly’s tirzepatide, and the market reacted fast.

We covered LLY earlier in the newsletter, and this move is a reminder that the weight loss race is not a two-horse parade.

Vanda jumped after the FDA approved Bysanti for bipolar I disorder and schizophrenia, which is the kind of headline that lights up small-cap biotech.

The next test is whether the follow-through holds once the market shifts from excitement to launch questions.

A new research report highlights 5 stocks with the strongest potential to double in the year ahead.

Each was selected from thousands of companies and shows a rare mix of:

Past versions of this report delivered gains of +175%, +498%, and even +673% — and the latest edition is free for a short time.

Available only until MIDNIGHT TONIGHT.

Download the free report

That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.

Best Regards,

— Adam Garcia
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.